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Transaminase-catalyzed continous synthesis of biogenic 
aldehydes 
Martina L. Contente[a] and Francesca Paradisi*[a][b] 
 
Dedication ((optional)) 
Abstract: The physiological role of biogenic aldehydes such as 
DOPAL has been associated with cardiovascular and 
neurodegenerative disorders. The availability of these substrates is 
limited and robust synthetic methodologies would greatly facilitate 
further biological studies. Here we report on transaminase mediated 
single-step process in continuous mode which leads to excellent 
product yields (90-95%). Co-immoblization of the PLP cofactor 
eliminated the need of exogenous addition of this reagent without 
affecting the longevity of the system, delivering a truly self-sufficient 
process. 
Aldehydes species are continuously generated in biological 
systems from a wide range of endogenous and exogenous 
precursors.1a Biogenic aldehydes are defined as those formed 
endogenously through enzyme-dependent or spontaneous 
oxidation of lipids, sugars and primary amines.1b-e Thanks to the 
strong electrophilicity of the terminal carbonyl group they are 
considered the most reactive compounds between 
biomolecules.2 If not metabolized, biogenic aldehydes can 
become cytotoxic due to covalent modifications or adduct 
formation with proteins (typically Cys, Lys, His, and Arg 
residues),3 nucleic acids (involving amino groups of both purines 
and pyrimidines)4 and coenzymes5 with subsequent inactivation 
via Michael addition, Knoevenagel  condensation, Shiff base, 
and free radical formation. Moreover aldehydes are relatively 
long-lived so they not only react with targets in their proximity 
but can also diffuse or be transported to remote sites.6 While, 
originally, biogenic aldehydes were believed to be innocuous 
intermediates predominantly formed by oxidative amination via 
monoamine oxidase (MAO), recent studies demonstrated that 
not only they are neurotransmitters themselves,7 but are also 
involved in the development of cardiovascular8 and 
neurodegenerative diseases (such as Alzheimer’s and 
Parkinson’s disease)7 and play a key role in alcohol-related 
disorders.2  
Synthetically, numerous attempts have been reported for the 
preparation of biogenic aldehydes.9a-d However, these 
methodologies require several steps, drastic reaction conditions, 
and repeated purifications. Li et al.10a-c described for the first time 
the synthesis and characterization of DOPAL (a metabolic 
intermediate deriving from dopamine) which required the use of 
restricted starting materials, (e.g., piperonal belonging to the list 
of the controlled substances under drug legislation), 
environmentally unfriendly conditions (strong acids or bases, 
toxic solvents and reagents such as benzene, POCl3 and 
mercury salts) to yield the desired products in low-to-moderate 
amounts (14-60%). More recently, Reimann et al.9c and Carosi et 
al.9d reported on the preparation of (3,4-dimethoxyphenyl)- and 
(3-methoxyphenyl)acetaldehyde respectively. Despite achieving 
better yields, both methodologies still require several reaction 
steps followed by purification, strong oxidizing reagents, and dry 
reaction environment.  
Enzymatically, just a few examples involving whole cells of 
Aspergillus niger11 with over-expressed MAO, partially purified 
MAO,12 and aromatic acetaldehyde synthases (AASs)13 are 
reported. In these cases, the formed aldehydes were usually 
transient intermediates of other reactions (e.g., Pictet-Spengler 
condensation), therefore no accumulation, purification or 
characterization were described. Moreover, the use of AASs, 
able to catalyze the decarboxylation-oxidative deamination of 
aromatic amino acids, lead to the production of additional 
byproducts such as NH3 and H2O2, which are generally toxic to 
the enzymes (increase in the pH, strong oxidizing reaction 
environment).  
Therefore, an alternative, reliable strategy for the preparation 
of biogenic aldehydes in reasonable quantities and purity, would 
enable tailored in-vitro and in-vivo studies to further probe their 
biological functions. Aldehydes may in fact be an index of the 
metabolism of newly formed catecolamines in patients with 
neurodegenerative diseases and could be linked to alterations of 
cardiovascular structures with consequent cell apoptosis. In 
addition, their availability as pure standard will allow accurate 
measurements in human and animal tissues and a better 
understanding of sources, reactivity, and pathological 
mechanism under conditions of compromised aldehydes 
detoxification. Some of these aldehydes are commercially 
available, however they can be expensive, especially if needed 
in larger amounts, and a simple synthesis from readily available 
starting materials would allow more competitive pricing. 
Cellular metabolism can be mimicked by assembling 
telescoped enzymatic reactions in flow bio-reactors which also 
significantly increases the efficiency and sustainability of the 
whole process.14 Recirculation of aqueous media containing 
recycled cofactors and recovery of benign by-products allowed 
for the development of ultra-efficient closed-loop flow-systems 
with excellent atom efficiency and automation.15 Within this work 
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biogenic aldehydes were produced as intermediates in the 
preparation  of the corresponding alcohols from amine starting 
materials, but were never accumulated, isolated or characterized.   
Key to the success of enzymatic reactions is the robustness 
and the reusability of the biocatalyst.16 Immobilization of ω-
transaminases has proven to be very efficient in increasing their 
operational stability and in the intensification of the productivity 
under flow conditions, including the preparation of a range of 
aldehydes from amines.17a-b In a further development, co-
immobilization of the cofactor PLP (pyridoxal phosphate) has 
shown to eliminate completely the requirement of exogenous 
addition of this reagent [18] which was otherwise routinely added 
to all transaminase mediated reactions to increase yields and 
longevity of the system.[19a-b]  
In this work we therefore exploited the co-immobilization of 
PLP with an ω-transaminase from the haloadapted bacterium 
Halomonas elongata (HEWT) for the synthesis of high value 
biogenic aldehydes in flow reactors. The system is self-
sufficient, mimics an in-vivo process, and it achieves excellent 
efficiency, sustainability and complete automation.  
The strategy (Scheme 1) was first optimized for the 
preparation of phenylacetaldehyde under flow conditions. 
Scheme 1. Solution A: 40 mM amine in HEPES buffer (10 mM pH 
7.5) Solution B: 40 mM pyruvate in HEPES buffer (10 mM pH 7.5). 
T= 37 °C. P= atm. Toluene (20%) is added upstream. 
 
In the co-immobilized system, HEWT (5 mg/gresin) was 
oriented and irreversibly bound through a multivalent 
attachment, while PLP (1 mM) through ionic bridges and 
reversible imine bonds was free to shuttle between the enzyme 
active sites without leaving the pore microenvironment of the 
resin (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Co-immobilization of HEWT and PLP 
 
PLP here is acting not only as co-factor for the 
biotrasformation of amines into aldehydes, but also as stabilizer 
for the enzyme structure. High availability of PLP prevents 
subunit dissociation stabilizing the quaternary structure of the 
enzyme. A similar stabilization effect was observed when 
soluble PLP was incubated with soluble HEWT.17a, 18  
Phenylacetaldehyde was obtained in high yield (>99%) and 
excellent residence time (15 min) when compared to batch 
methods (240 min, >99% of m.c.). The continuous synthesis 
showed a 2.3-fold increase in reaction rate with respect to batch 
strategies (batch mode: 0.83 μmol/min gcatalyst - flow mode:1.9 
μmol/min gcatalyst). The use of pyruvate as amino acceptor 
strongly favors the equilibrium of the reaction generating ʟ-
alanine as benign side product.[15,17b,20] A segmented flow (20:80 
toluene/HEPES buffer) was implemented to strip the newly 
generated aldehyde from the carrier and, through acidification 
downstream of the reactor, the product was extracted in‐line and 
recovered as pure compound without any further manipulation. 
The presence of toluene had no effect on the catalytic efficiency 
of the co-immobilized system which was extensively used over 
several days.  
Once optimal reaction conditions had been established, the 
system was tested with biogenic amines (Table 1). 
 
Table 1. Flow bio-synthesis of biogenic aldehydes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 20 mM amine 
b Determined by HPLC 
Residence Time = 15 min 
 
The functional group interconversion was consistently 
achieved with excellent reaction time (15 min). Interestingly, 
these set of amines did not behave like phenylacetaldehyde 
when tested in batch mode; here the aldehydes appeared to 
readily react with unreacted amines preventing the detection or 
characterization of any reasonable quantities of aldehydes. The 
addition of toluene in batch set up did not show any increase in 
the aldehyde detection. The flow approach in this case, resolves 
completely this drawback as it minimizes cross-condensation of 
Entry Substratea 
m.c. 
 (%)b 
Yield 
(%) 
1 
 
  97 90 
2 
 
  98 93 
3 
 
>99 94 
4 
 
>99 95 
5 
 
  96 90 
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product and starting material, affording excellent process yields 
(90-95%).  
Isolated enzymes, when compared with partially purified 
fractions or whole cells biotransformations, behave more 
similarly to traditional catalysts and generally do not cause side 
reactions, and of course never encounter permeability problems. 
In particular transaminases, with respect to MAO or AASs, offer 
a better control of the deamination step which does not generate 
NH3 or H2O2 as the amino group is simply transferred onto a 
sacrificial acceptor. Both NH3 or H2O2, if let to accumulate in the 
reaction vessel, can cause pH increase as well as strong 
oxidizing reaction environment, which could eventually inactivate 
the enzyme involved in the biotransformations (even under flow 
conditions). HEWT, when pyruvate is the amino acceptor, forms 
ʟ-alanine that can be easily recovered via scavenging columns 
as previously reported15. Notably HEWT is completely stable 
under segmented flow (buffer/toluene), and the same packed 
bed reactor was used to perform all the experiments without any 
loss of the activity. 
In summary a new strategy for the synthesis of aromatic 
biogenic aldehydes was developed. HEWT was further 
stabilized due to the co-immobilization with PLP producing a 
self-sufficient heterogeneous biocatalyst for deamination 
reaction without exogenous addition of cofactors.  In addition, 
with respect to previously reported data on amine conversion,17b 
here the concentration of the starting material was doubled and 
still yields of 90-95% were achieved. Side condensation 
reactions typically present in the batch methods were never 
observed.  
The in-line extraction step allowed for the separation and 
recovery of the pure biogenic aldehydes in the toluene stream, 
while ʟ-alanine/ traces of unreacted amines remained in the 
water phase, with no further work-up procedure making the 
process fully automated. 
The combination of continuous mode and biocatalysis not only 
leads to significant reduction of the reaction times (15 min) and 
increased productivity but also has established a highly 
sustainable routes to an array of valuable products. 
 
Experimental Section 
Expression, purification, and immobilization of HEWT in E. coli 
Protein expression and purification was performed following previously 
reported protocols in Cerioli et al.20 Immobilization was conducted 
according to the procedure reported by Benítez-Mateo et al.18 The 
retained activity observed for the co-immobilized HEWT/PLP system was 
>50% with respect to the free form with exogenously added cofactor (free 
enzyme: 5 U/mg, immobilized system 2.6 U/mg). 
 
Batch reactions with immobilized HEWT 
 
Batch reactions using the imm-HEWT with co-immobilized PLP were 
performed in 1.5 mL micro centrifuge tubes; 500 μL reaction mixture in 
10 mM HEPES buffer pH 7.5, containing 20 mM pyruvate, 20 mM amino 
donor substrate and 50 mg of imm-HEWT with co-immobilized PLP (5 
mg/gresin, 1 mM PLP) was left under gentile shaking at 37 °C. 10 μL 
aliquots were quenched with a 50:50 mixture of hydrochloric acid (HCl) 
0.2%:acetonitrile solution every hour and then analyzed by LC-MS 
equipped with a Waters X-Bridge C18 (3.5 µm, 2.1 mm x 30.0 mm). The 
compounds were detected using a DAD detector at 250 nm after a 5 min 
gradient run (A: 0.1% Ammonia in water, B: Acetonitrile. Gradient: 0 min 
5% A 95% B; 3.10 min 0% A 100% B; 3.50 min 0% A 100% B; 3.51 min 
95% A 5% B; 4.50 min 95% A 5% B. Injection volume 2 µL) at 40 °C with 
a flow rate of 0.8 mL/min. The retention times in minutes were: 2-
phenylethylamine (2.0 min), 2-phenylacetaldehyde (2.3 min). 
 
Flow reactions with immobilized HEWT and co-immobilized PLP 
 
Continuous flow biotransformations were performed using a R2+/R4 
Vapourtec flow reactor equipped with an Omnifit glass column (6.6 mm 
i.d. × 100 mm length) filled with 1.3 g of imm-HEWT/Co-immobilized PLP 
(5 mg/gresin 1 mM PLP). 40 mM sodium pyruvate in HEPES buffer (10 
mM, pH 7.5) and 40 mM amino donor solutions were prepared. The two 
solutions were mixed in a T-piece. A second junction for additional 
supplement of toluene was installed before the packed enzyme column. 
The resulting segmented flow stream (80:20 buffer/toluene) was directed 
to the imm-HEWT/co-imm PLP (reactor volume: 1.8 mL, flow rate: 0.12 
mL/min). An in-line acidification was performed by using an inlet of 1 N 
HCl aqueous solution (flow rate: 0.1 mL/min) that was mixed to the 
exiting reaction flow stream using a T-junction. After an in-line extraction 
using a Zaiput liquid-liquid separator, the organic and aqueous phases 
were  analyzed by HPLC exploiting a calibration curve and the toluene 
containing the desired product was evaporated to yield the aldehydes. 
 
Analysis of biogenic aldehydes reactions 
 
The flow biotransformations were analyzed by a Thermo Ultimate 300s 
HPLC equipped with a Accucore™ C18 LC Column (2.6 µm, 4.6 mm x 
150 mm). The mobile phase was composed by A: 0.05% formic acid in 
water, B: Acetonitrile. The compounds were detected using a DAD 
detector at 280 nm after a gradient run increasing the concentration of  B 
as follows:  0-5 min 10%, 5-10 min 50%, 10-11 min 10% (Injection 
volume 10 µL) at 40 °C with and flow rate of 1 mL/min. The retention 
times in minutes were: dopamine (2.7 min); DOPAL (3.4 min); 3,4-
methoxyphenetilamine (3.4 min); 3,4-methoxyphenylacetaldehyde (4.2 
min); 4-hydroxyphenetilamine (2.9 min); 4-hydroxyphenylacetaldehyde 
(3.5 min); 4-methoxyphenetilamine (3.2 min); 4-
methoxyphenylacetaldehyde (4.0 min); 3-methoxyphenetilamine (3.0 
min); 3-methoxyphenylacetaldehyde (3.8 min). The isolated aldehydes 
were further characterized by 1H-NMR spectra which corresponded to 
those previously reported in literature. 
 
Reaction rate comparison between batch and flow mode 
 
Specific reaction rates in batch and continuous-flow systems were 
calculated using the following equations:21 
Equation 1. 
rbatch = ƞp / t mb (µmol / min g) 
where [ƞp] is the amount of product (expressed as µmol), t  is the reaction 
time (expressed as min), and mb [g] is the amount of biocatalyst 
employed.  
Equation 2. 
rflow = [P]x f / mb (µmol / min g) 
where [P] is the product concentration flowing out of the reactor 
(expressed as µmol mL-1), f is the flow rate (expressed as mL min-1), and 
mb [g] is the amount of biocatalyst loaded in the column. 
 
Characterization of the products 
 
The purity of aldehydes was assessed by HPLC and 1H NMR. 1H NMR 
spectra were recorded with a Varian Mercury 300 (300 MHz) 
spectrometer. Chemical shifts (δ) are expressed in ppm, and coupling 
constants (J) are expressed in Hz. 
 
3,4-Dihydroxyphenylacetaldehyde (DOPAL): NMR (300 MHz, DMSO-d6) 
δ (ppm): 9.58 (t, J = 2.33 Hz, 1H ), 6.70 (d, J = 7.99 Hz, 1H), 6.61 (d, J = 
2.13 Hz, 1H), 6.47 (dd, J = 7.99, 2.13 Hz, 1H), 3.52 (d, J = 2.40 Hz, 2H), 
2.85 (t, J = 7.3 Hz, 2H), 1.93 (s, 3H). 
 
3,4-Dimethoxyphenylacetaldehyde:NMR (300 MHz, CDCl3) δ (ppm): 9.75 
(t, J = 2.45 Hz, 1H ), 6.89 (d, J = 8.15 Hz, 1H), 6.81 (dd, J = 8.15, 2.05 
Hz, 1H), 6.73 (d, J = 2.0 Hz, 1H), 3.98 (s, 6H), 3.65 (d, J = 2.48 Hz, 2H). 
 
4-Hydroxyphenylacetaldehyde: NMR (300 MHz, DMSO-d6) δ (ppm): 9.62 
(t, J = 2.18 Hz, 1H ), 9.34 (s, 1H), 7.03 (m, 2H), 6.74 (m, 2H), 6.73 (d, J = 
2.0 Hz, 1H), 3.98 (s, 6H), 3.61 (d, J = 2.20 Hz, 2H). 
 
4-Methoxyphenylacetaldehyde: NMR (300 MHz, DMSO-d6) δ (ppm): 
9.65 (t, J = 2.03 Hz, 1H ), 7.16 (m, 2H), 6.92 (m, 2H), 6.73 (d, J = 2.0 Hz, 
1H), 3.74 (s, 3H), 3.68 (d, J = 2.09 Hz, 2H). 
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3-Methoxyphenylacetaldehyde: NMR (300 MHz, CDCl3) δ (ppm): 9.73 (t, 
J = 2.40 Hz, 1H ), 7.31-7.26 (m, 1H), 6.85-6.74 (m, 3H), 3.82 (s, 3H), 
3.65 (d, J = 2.48 Hz, 2H) . 
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